Skip to main content

Advertisement

Table 1 Baseline characteristics

From: High-density lipoprotein cholesterol for the prediction of mortality in cirrhosis with portal vein thrombosis: a retrospective study

  Entire group N = 117 Non-survivors N = 15 Survivors N = 102 p value
Age (year) 55.96 ± 11.90 59.87 ± 12.31 55.38 ± 11.79 0.174
Gender     0.145
 Male 73 (62.4) 7 (46.7) 66 (64.7)  
 Female 44 (37.6) 8 (53.3) 36 (35.3)  
BMI (kg/m2) 23.60 ± 2.51 24.01 ± 1.82 23.54 ± 2.60 0.440
Child score (n, %) 7.39 ± 1.43 8.53 ± 1.64 7.23 ± 1.33 < 0.01**
 A 33 (28.2) 2 (13.3) 31 (30.4)  
 B 74 (63.2) 8 (53.3) 66 (64.7)  
 C 10 (8.6) 5 (33.3) 5 (4.9)  
MELD score 9.75 ± 1.80 11.67 ± 1.72 9.67 ± 1.63 < 0.001***
Etiology (n, %)     0.067
 Virus 53 (45.3) 5 (33.3) 59 (47.1)  
 Others 64 (54.7) 10 (66.7) 43 (42.2)  
  Schistosome 10 2 8  
  PBC 4 2 2  
  Alcoholic 9 1 8  
  Autoimmune 6 1 5  
  NAFLD 6 1 5  
  Unknown 18 3 15  
Smoking history (n, %) 25 (21.4) 5 (33.3) 20 (19.6) 0.188
Drinking history (n, %) 14 (12.0) 3 (20) 11 (10.8) 0.257
Extent of PVT (n, %)     0.655
 MPV or branches 44 (37.6) 4 (26.7) 40 (39.2)  
 SMV/SV 61 (52.1) 9 (60) 52 (60)  
 Cavernous 12 (10.3) 2 (13.3) 10 (9.8)  
Degree of PVT (n, %)     0.243
 Partial 57 (48.7) 7 (46.7) 50 (49.0)  
 Complete 48 (41.0) 6 (40) 42 (41.2)  
 Cavernous 12 (10.3) 2 (13.3) 10 (9.8)  
Ascites (n, %)     0.073
 Mild 23 (19.7) 2 (13.3) 21 (20.6)  
 Moderate 32 (27.4) 1 (6.7) 31 (30.4)  
 Severe 62 (52.9) 12 (80.0) 50 (49.0)  
Splenectomy history (n, %) 56 (47.9) 4 (26.7) 52 (51.0) 0.100
Prothrombotic (n, %)     0.052
 Protein C deficiency 2 (1.7) 1 (6.7) 1 (1.0)  
 Protein S deficiency 5 (4.3) 2 (13.3) 3 (2.9)  
 JAK2V617F mutation 0 (0.0) 0 (0.0) 0 (0.0)  
 Others 0 (0.0) 0 (0.0) 0 (0.0)  
Treatment (n, %)     0.065
 TIPS 57 (48.7) 6 (40) 51 (50)  
 EBL+ propranolol 34 (29.1) 2 (13.3) 32 (31.4)  
 Others 26 (22.2) 7 (46.7) 19 (18.6)  
Anticoagulant (n, %) 83 (70.9) 13 (86.7) 70 (68.6) 0.225
Indication for TIPS (n, %)     0.893
 Variceal bleeding 12 (12/57) 1 (1/6) 11 (11/51)  
 Ascites 4 (4/57) 0 (0/6) 4 (4/51)  
 PVT 6 (6/57) 1 (1/6) 5 (5/51)  
 PVT and bleeding 35 (35/57) 4 (4/6) 31 (31/51)  
PVT progression (n, %)     0.131
 Improved 19 (16.2) 4 (33.3) 15 (18.6)  
 Stable 34 (29.1) 4 (26.7) 30 (29.4)  
 Worsened 10 (8.6) 3 (20) 7 (23.6)  
 Unknown 54 (46.2) 4 (26.7) 50 (49.0)  
Causes of death (n, %)    
 Liver failure 7 (46.7)  
 GI bleeding 5 (33.3)  
 Encephalopathy 3 (20)  
1-year mortality rate (%) 12.8%
Laboratory
 INR 1.3 (1,3.4) 1.26(1.12,1.66) 1.3 (1,3.4) 0.220
 Platelet (*10^9/L) 111 (22,416) 95 (30,276) 125 (22,416) 0.835
 WBC (*10^9/L) 4.2 (0.7,32.4) 5.1 (1.1,32.4) 4.2 (0.7,28) 0.264
 Hemoglobin (g/L) 79 (43,152) 92 (56,152) 78.5 (43,148) 0.160
 Bilirubin (umol/L) 18.6(3.9133.6) 26.2(8.9133.6) 17.6 (3.9116) 0.011*
 Albumin (g/L) 32.34 ± 4.17 30.12 ± 5.18 32.62 ± 4.03 0.033*
 ALT (U/L) 18.4(4.6162.4) 23.9 (8.1,44.9) 17.65(4.6162.4) 0.403
 AST (U/L) 29.8(9.9230.1) 37.4 (19,114.3) 28.55(9.9230.1) 0.065
 AST/ALT ratio 1.48 (0.63,6.6) 1.75(0.93,4.62) 1.47(0.63,6.6) 0.142
 CRP (mg/L) 5.1 (0.2137.7) 21.2 (1.2,77.7) 4.4(0.2137.7) < 0.01**
 Creatinine (umol/L) 60 (32,210) 63 (37,111) 60 (32,210) 0.744
Lipid profile
 Triglyceride (mmol/L) 0.68(0.16,4.93) 0.83(0.43,1.29) 0.67(0.16,4.93) 0.095
 Cholesterol (mmol/L) 3.04 (1.2,5.7) 2.75(1.66,4.63) 3.06 (1.2,5.7) 0.841
 HDL-C (mmol/L) 0.81(0.14,1.92) 0.40(0.14,0.96) 0.83(0.16,1.92) < 0.01**
 LDL-C (mmol/L) 1.58(0.58,3.88) 1.60(0.66,3.02) 1.58(0.58,3.88) 0.708
  1. *indicated for statistically significant with p < 0.05; ** indicated for p value< 0.01;
  2. ***indicated for p value< 0.001; NAFLD nonalcoholic fatty liver disease, TIPS transjugular intrahepatic portosystemic shunts, EBL endoscopic band ligation, GI gastric intestinal